Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Findings In Epilepsy Gene In Animals May Guide Treatment Directions For Infants
Researchers studying a difficult-to-treat form of childhood epilepsy called infantile spasms have developed a line of mice that experiences seizures with features closely resembling those occurring in patients with infantile seizures. These genetically engineered mice provide a new opportunity for scientists to test treatments that may benefit children.

Ohio Department Of Health Confirms First H1N1 Influenza Death
The Ohio Department of Health (ODH) announced that a Butler County male in his 40s, who was infected with H1N1 influenza, died June 29. This is the first Ohio death linked to the pandemic strain of influenza. The patient had underlying health problems that may have contributed to his death.
News of the day
Labopharm Files New Drug Submission With Health Canada For Novel Antidepressant
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) announced it has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada for its novel formulation of the antidepressant trazodone.
Endocrinology

NICE Welcomes Office For Life Sciences New Blueprint To Support Innovative Drugs

NICE today welcomed the Office for Life Sciences new Blueprint to support the life sciences industry, which will also improve patient access to innovative new drugs. Welcoming the Blueprint launch, Andrew Dillon Chief Executive of NICE said: "Securing a successful future for the life sciences industries is important for patients and the UK economy.The Innovation Pass is an opportunity for data to be gathered on potentially important new treatments. NICE has been involved in discussions about the Innovation Pass, and we are looking forward to continuing to play a key role in developing the pass." Mr Dillon continued: "NICE is committed to engaging constructively with the pharmaceutical industry and we are extending the access that companies have to us, as we appraise their products. Later this year, we will begin asking pharmaceutical and other life sciences companies, whose products we are evaluating, to make technical staff available to engage with our advisory Appraisal Committees. They will be able to respond to requests from committee chairs to clarify the data they have submitted and to point out any error of fact in the presentation of their data. We believe that this will give companies more confidence in the way NICE handles the evaluation of their products." NICE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009